These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 17982121

  • 1. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
    Song J, Shih IeM, Salani R, Chan DW, Zhang Z.
    Clin Cancer Res; 2007 Nov 15; 13(22 Pt 1):6842-9. PubMed ID: 17982121
    [Abstract] [Full Text] [Related]

  • 2. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 15; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 3. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
    Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K, Kuwano M, Nakano H.
    J Cancer Res Clin Oncol; 2002 Nov 15; 128(11):621-6. PubMed ID: 12458343
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS.
    Gynecol Oncol; 2005 Apr 15; 97(1):110-7. PubMed ID: 15790446
    [Abstract] [Full Text] [Related]

  • 5. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S, Ma D.
    Gynecol Oncol; 2005 May 15; 97(2):413-21. PubMed ID: 15863139
    [Abstract] [Full Text] [Related]

  • 6. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L.
    Gynecol Oncol; 2007 Apr 15; 105(1):31-44. PubMed ID: 17275076
    [Abstract] [Full Text] [Related]

  • 7. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
    Aggarwal S, He T, Fitzhugh W, Rosenthal K, Feild B, Heidbrink J, Mesmer D, Ruben SM, Moore PA.
    Gynecol Oncol; 2009 Dec 15; 115(3):430-7. PubMed ID: 19800108
    [Abstract] [Full Text] [Related]

  • 8. [Expression of lung resistant-related protein in ovarian cancer and its clinical significance].
    Qian XL, Peng ZL, Liu SL, Wang H, Ni J.
    Ai Zheng; 2002 Dec 15; 21(12):1332-4. PubMed ID: 12520742
    [Abstract] [Full Text] [Related]

  • 9. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.
    Clin Cancer Res; 2005 Aug 15; 11(16):6030-9. PubMed ID: 16115948
    [Abstract] [Full Text] [Related]

  • 10. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
    Hille S, Rein DT, Riffelmann M, Neumann R, Sartorius J, Pfützner A, Kurbacher CM, Schöndorf T, Breidenbach M.
    Anticancer Drugs; 2006 Oct 15; 17(9):1041-4. PubMed ID: 17001177
    [Abstract] [Full Text] [Related]

  • 11. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Leong CT, Ong CK, Tay SK, Huynh H.
    Oncogene; 2007 Feb 08; 26(6):870-80. PubMed ID: 16862170
    [Abstract] [Full Text] [Related]

  • 12. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W, Ke S, Chen G, Gao Q, Wu S, Wang S, Zhou J, Yang X, Lu Y, Ma D.
    Oncol Rep; 2004 Dec 08; 12(6):1365-70. PubMed ID: 15547764
    [Abstract] [Full Text] [Related]

  • 13. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
    Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, deFazio A.
    Clin Cancer Res; 2008 Nov 01; 14(21):6924-32. PubMed ID: 18980987
    [Abstract] [Full Text] [Related]

  • 14. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Santin AD, Cané S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S.
    Cancer Res; 2005 May 15; 65(10):4334-42. PubMed ID: 15899825
    [Abstract] [Full Text] [Related]

  • 15. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
    Qian XL, Peng ZL, Liu SL.
    Ai Zheng; 2003 Dec 15; 22(12):1352-4. PubMed ID: 14693068
    [Abstract] [Full Text] [Related]

  • 16. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
    Le Moguen K, Lincet H, Deslandes E, Hubert-Roux M, Lange C, Poulain L, Gauduchon P, Baudin B.
    Proteomics; 2006 Oct 15; 6(19):5183-92. PubMed ID: 16941573
    [Abstract] [Full Text] [Related]

  • 17. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y, Wang J, Xiang D, Wang D, Xin X.
    Int J Oncol; 2009 Nov 15; 35(5):1069-79. PubMed ID: 19787261
    [Abstract] [Full Text] [Related]

  • 18. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
    Yan XD, Pan LY.
    Zhonghua Fu Chan Ke Za Zhi; 2006 Sep 15; 41(9):584-7. PubMed ID: 17181965
    [Abstract] [Full Text] [Related]

  • 19. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M, Miyazaki K.
    Clin Cancer Res; 2008 May 15; 14(10):3149-55. PubMed ID: 18483383
    [Abstract] [Full Text] [Related]

  • 20. Heterogeneity of drug resistance in human breast and ovarian cancers.
    Kern DH.
    Cancer J Sci Am; 1998 May 15; 4(1):41-5. PubMed ID: 9467045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.